1
|
Steinmetz-Späh J, Arefin S, Larsson K, Jahan J, Mudrovcic N, Wennberg L, Stenvinkel P, Korotkova M, Kublickiene K, Jakobsson PJ. Effects of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition on resistance artery tone in patients with end stage kidney disease. Br J Pharmacol 2021; 179:1433-1449. [PMID: 34766335 DOI: 10.1111/bph.15729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 10/13/2021] [Accepted: 10/18/2021] [Indexed: 12/01/2022] Open
Abstract
BACKGROUND Inhibition of the microsomal prostaglandin (PG) E2 synthase (mPGES-1) introduces a promising anti-inflammatory treatment approach by specifically reducing PGE2 . The microvasculature is a central target organ for early manifestations of cardiovascular disease. Therefore, a better understanding of the prostaglandin system and characterising the effects of mPGES-1 inhibition in this vascular bed are of interest. EXPERIMENTAL APPROACH The effects of mPGES-1 inhibition on constriction and relaxation of resistance arteries (Ø100-400μm) from patients with end stage kidney disease (ESKD) and controls (Non-ESKD) were studied using wire-myography in combination with immunological and mass-spectrometry based analyses. KEY RESULTS Inhibition of mPGES-1 in arteries from ESKD patients and Non-ESKD controls significantly reduced adrenergic vasoconstriction, which was not affected by the COX-2 inhibitors NS-398 and Etoricoxib or the COX-1/COX-2 inhibitor Indomethacin, tested in Non-ESKD controls. Correspondingly, a significant increase of acetylcholine-induced dilatation was observed for mPGES-1 inhibition only. In IL-1β treated arteries, inhibition of mPGES-1 significantly reduced PGE2 levels while PGI2 levels remained unchanged. In contrast, COX-2 inhibition blocked the formation of both prostaglandins. Blockage of PGI2 signaling with an IP receptor antagonist did not restore the reduced constriction, neither did blocking of PGE2 -EP4 or signaling through PPARγ. A biphasic effect was observed for PGE2 , inducing dilatation at nmol and constriction at μmol concentrations. Immunohistochemistry demonstrated expression of mPGES-1, COX-1, PGIS, weak expression for COX-2 as well as receptor expression for PGE2 (EP1-4), thromboxane (TP) and PGI2 (IP) in ESKD and Non-ESKD. CONCLUSION Our study demonstrates vasodilating effects following mPGES-1 inhibition in human microvasculature and suggests that several pathways besides shunting to PGI2 may be involved.
Collapse
Affiliation(s)
- Julia Steinmetz-Späh
- Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet & Karolinska University Hospital, Stockholm, Sweden
| | - Samsul Arefin
- Division of Renal Medicine, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska University Hospital, Stockholm, Sweden
| | - Karin Larsson
- Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet & Karolinska University Hospital, Stockholm, Sweden
| | - Jabin Jahan
- Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet & Karolinska University Hospital, Stockholm, Sweden
| | - Neja Mudrovcic
- Division of Renal Medicine, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska University Hospital, Stockholm, Sweden
| | - Lars Wennberg
- Division of Transplantation Surgery, Department of Clinical Science, Intervention and Technology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
| | - Peter Stenvinkel
- Division of Renal Medicine, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska University Hospital, Stockholm, Sweden
| | - Marina Korotkova
- Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet & Karolinska University Hospital, Stockholm, Sweden
| | - Karolina Kublickiene
- Division of Renal Medicine, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska University Hospital, Stockholm, Sweden
| | - Per-Johan Jakobsson
- Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet & Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
2
|
Avendaño MS, García-Redondo AB, Zalba G, González-Amor M, Aguado A, Martínez-Revelles S, Beltrán LM, Camacho M, Cachofeiro V, Alonso MJ, Salaices M, Briones AM. mPGES-1 (Microsomal Prostaglandin E Synthase-1) Mediates Vascular Dysfunction in Hypertension Through Oxidative Stress. Hypertension 2018; 72:492-502. [PMID: 29891646 DOI: 10.1161/hypertensionaha.118.10833] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2018] [Revised: 01/28/2018] [Accepted: 05/15/2018] [Indexed: 12/14/2022]
Abstract
mPGES-1 (microsomal prostaglandin E synthase-1), the downstream enzyme responsible for PGE2 (prostaglandin E2) synthesis in inflammatory conditions and oxidative stress are increased in vessels from hypertensive animals. We evaluated the role of mPGES-1-derived PGE2 in the vascular dysfunction and remodeling in hypertension and the possible contribution of oxidative stress. We used human peripheral blood mononuclear cells from asymptomatic patients, arteries from untreated and Ang II (angiotensin II)-infused mPGES-1-/- and mPGES-1+/+ mice, and vascular smooth muscle cells exposed to PGE2 In human cells, we found a positive correlation between mPGES-1 mRNA and carotid intima-media thickness (r=0.637; P<0.001) and with NADPH oxidase-dependent superoxide production (r=0.417; P<0.001). In Ang II-infused mice, mPGES-1 deletion prevented all of the following: (1) the augmented wall:lumen ratio, vascular stiffness, and altered elastin structure; (2) the increased gene expression of profibrotic and proinflammatory markers; (3) the increased vasoconstrictor responses and endothelial dysfunction; (4) the increased NADPH oxidase activity and the diminished mitochondrial membrane potential; and (5) the increased reactive oxygen species generation and reduced NO bioavailability. In vascular smooth muscle cells or aortic segments, PGE2 increased NADPH oxidase expression and activity and reduced mitochondrial membrane potential, effects that were abolished by antagonists of the PGE2 receptors (EP), EP1 and EP3, and by JNK (c-Jun N-terminal kinase) and ERK1/2 (extracellular-signal-regulated kinases 1/2) inhibition. Deletion of mPGES-1 augmented vascular production of PGI2 suggesting rediversion of the accumulated PGH2 substrate. In conclusion, mPGES-1-derived PGE2 is involved in vascular remodeling, stiffness, and endothelial dysfunction in hypertension likely through an increase of oxidative stress produced by NADPH oxidase and mitochondria.
Collapse
Affiliation(s)
- María S Avendaño
- From the Departmento de Farmacología, Instituto de Investigación Hospital La Paz, Universidad Autónoma de Madrid, Spain (M.S.A., A.B.G.-R., M.G.-A., A.A., S.M.-R., M.S., A.M.B.)
| | - Ana B García-Redondo
- From the Departmento de Farmacología, Instituto de Investigación Hospital La Paz, Universidad Autónoma de Madrid, Spain (M.S.A., A.B.G.-R., M.G.-A., A.A., S.M.-R., M.S., A.M.B.).,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares, Madrid, Spain (A.B.G.-R., S.M.-R., M.C., V.C., M.J.A., M.S., A.M.B.)
| | - Guillermo Zalba
- Departamento de Bioquímica y Genética, Instituto de Investigación Sanitaria de Navarra, Universidad de Navarra, Pamplona, Spain (G.Z.)
| | - María González-Amor
- From the Departmento de Farmacología, Instituto de Investigación Hospital La Paz, Universidad Autónoma de Madrid, Spain (M.S.A., A.B.G.-R., M.G.-A., A.A., S.M.-R., M.S., A.M.B.)
| | - Andrea Aguado
- From the Departmento de Farmacología, Instituto de Investigación Hospital La Paz, Universidad Autónoma de Madrid, Spain (M.S.A., A.B.G.-R., M.G.-A., A.A., S.M.-R., M.S., A.M.B.)
| | - Sonia Martínez-Revelles
- From the Departmento de Farmacología, Instituto de Investigación Hospital La Paz, Universidad Autónoma de Madrid, Spain (M.S.A., A.B.G.-R., M.G.-A., A.A., S.M.-R., M.S., A.M.B.).,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares, Madrid, Spain (A.B.G.-R., S.M.-R., M.C., V.C., M.J.A., M.S., A.M.B.)
| | - Luis M Beltrán
- Unidad Clínico-Experimental de Riesgo Vascular-Medicina Interna, Instituto de Biomedicina de Sevilla, Hospital Virgen del Rocío, Spain (L.M.B.)
| | - Mercedes Camacho
- Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares, Madrid, Spain (A.B.G.-R., S.M.-R., M.C., V.C., M.J.A., M.S., A.M.B.).,Laboratorio de Angiología, Biología Vascular e Inflamación, Instituto de Investigación Biomédica Sant Pau, Barcelona, Spain (M.C.)
| | - Victoria Cachofeiro
- Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares, Madrid, Spain (A.B.G.-R., S.M.-R., M.C., V.C., M.J.A., M.S., A.M.B.).,Departamento de Fisiología, Facultad de Medicina, Instituto de Investigación Gregorio Marañón, Universidad Complutense de Madrid, Spain (V.C.)
| | - María J Alonso
- Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares, Madrid, Spain (A.B.G.-R., S.M.-R., M.C., V.C., M.J.A., M.S., A.M.B.).,Departamento de Ciencias Básicas de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain (M.J.A.)
| | - Mercedes Salaices
- From the Departmento de Farmacología, Instituto de Investigación Hospital La Paz, Universidad Autónoma de Madrid, Spain (M.S.A., A.B.G.-R., M.G.-A., A.A., S.M.-R., M.S., A.M.B.).,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares, Madrid, Spain (A.B.G.-R., S.M.-R., M.C., V.C., M.J.A., M.S., A.M.B.)
| | - Ana M Briones
- From the Departmento de Farmacología, Instituto de Investigación Hospital La Paz, Universidad Autónoma de Madrid, Spain (M.S.A., A.B.G.-R., M.G.-A., A.A., S.M.-R., M.S., A.M.B.) .,Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares, Madrid, Spain (A.B.G.-R., S.M.-R., M.C., V.C., M.J.A., M.S., A.M.B.)
| |
Collapse
|
3
|
Ohtake T, Sato M, Nakazawa R, Kondoh M, Miyaji T, Moriya H, Hidaka S, Kobayashi S. Randomized Pilot Trial Between Prostaglandin I2Analog and Anti-Platelet Drugs on Peripheral Arterial Disease in Hemodialysis Patients. Ther Apher Dial 2013; 18:1-8. [DOI: 10.1111/1744-9987.12051] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Takayasu Ohtake
- Department of Nephrology, Immunology, and Vascular Medicine; Shonan Kamakura General Hospital; Kamakura Japan
| | - Motoyoshi Sato
- Department of Kidney and Dialysis; Social Insurance Chukyo Hospital; Nagoya Japan
| | | | - Morihiro Kondoh
- Department of Nephrology; Rakuwakai Otowa Memorial Hospital; Kyoto Japan
| | | | - Hidekazu Moriya
- Department of Internal Medicine; Shonan Atsugi Hospital; Atsugi Japan
| | - Sumi Hidaka
- Department of Nephrology, Immunology, and Vascular Medicine; Shonan Kamakura General Hospital; Kamakura Japan
| | - Shuzo Kobayashi
- Department of Nephrology, Immunology, and Vascular Medicine; Shonan Kamakura General Hospital; Kamakura Japan
| |
Collapse
|
4
|
Gwon SH, Kim SG. One-Pot Cascade Michael-Cyclization Reactions of o-Hydroxycinnamaldehydes: Synthesis of Functionalized 2,3-Dihydrobenzofuranes. B KOREAN CHEM SOC 2012. [DOI: 10.5012/bkcs.2012.33.8.2781] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
5
|
Takahashi M, Shiba T, Hirano K, Hitsumoto T, Shirai K. Acute decrease of cardio-ankle vascular index with the administration of beraprost sodium. J Atheroscler Thromb 2012; 19:479-84. [PMID: 22659532 DOI: 10.5551/jat.9266] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
AIM A novel arterial stiffness index, the cardio-ankle vascular index (CAVI), has been proposed. To clarify the properties of CAVI, the effects of beraprost sodium (BPS), a prostaglandin (PG) I2 analogue, which has a potent vasodilating effect, on CAVI were studied and comparing with brachialankle pulse wave velocity (baPWV) in healthy volunteers. METHODS Male volunteers (n=18, 46.3±4.2 yr) were enrolled in this study and administered BPS (40 µg). CAVI and baPWV were measured every hour for 4 hours. RESULTS When BPS was administered to 18 healthy volunteers, systolic blood pressure and diastolic blood pressure fluctuated slightly, but the means did not change. CAVI significantly decreased in the 1st hour from 8.3±0.34 (mean±SE) to 7.9±0.34 (p<0.05) and this decrease persisted for 3 hours, whereas baPWV did not significantly change. ΔbaPWV each time was significantly correlated with both Δsystolic blood pressure and Δdiastolic blood pressure, but ΔCAVI did not correlate with either Δsystolic blood pressure (r=-0.12, p=0.38) or Δdiastolc blood pressure (r=-0.22, p=0.10). CONCLUSIONS Beraprost sodium did not decrease blood pressure, but decreased CAVI, whereas baPWV did not change. These results indicate that CAVI partly reflected the contraction of arterial smooth muscle cells.
Collapse
Affiliation(s)
- Mao Takahashi
- Department of Internal Medicine, Sakura Hospital, Medical Center, Toho University, Chiba, Japan.
| | | | | | | | | |
Collapse
|
6
|
Abstract
Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterized by a persistent elevation of pulmonary artery pressure accompanied by right ventricular hypertrophy (RVH). The current treatment for pulmonary hypertension is limited and only provides symptomatic relief due to unknown cause and pathogenesis of the disease. Both vasoconstriction and structural remodeling (enhanced proliferation of vascular smooth muscle cell) of the pulmonary arteries contribute to the progressive course of PAH, irrespective of different underlying causes. The exact molecular mechanism of PAH, however, is not fully understood. The purpose of this review is to provide recent advances in the mechanistic investigation of PAH. Specifically, this review focuses on nitric oxide, oxidative stress and inflammation and how these factors contribute to the development and progression of PAH. This review also discusses recent and potential therapeutic advancements for the treatment of PAH.
Collapse
|
7
|
Kumakura H, Kanai H, Araki Y, Koizumi A, Kasama S, Sumino H, Ichikawa S. Effects of Antiplatelet Agents and Other Factors on Neointimal Proliferation in Iliac Artery Stenting: Intravascular Ultrasound Analysis. Ann Vasc Dis 2009. [DOI: 10.3400/avd.oa08022] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Kim KM, Kim HW, Lee JH, Chang JW, Park JS, Kim SB. Effects of Beraprost Sodium, An Oral Prostaglandin I2 Analog, on Hemostatic Factors and Inflammation in Chronic Peritoneal Dialysis Patients. Perit Dial Int 2008. [DOI: 10.1177/089686080902900212] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Beraprost sodium, an orally active prostaglandin I2 analog with vasodilatory, cytoprotective, antiplatelet, antithrombotic, and anti-inflammatory effects, 120 μg daily for 8 weeks, decreased plasma D-dimer, a marker of intravascular coagulation, and von Willebrand factor, a marker for endothelial injury, in 100 chronic peritoneal dialysis patients. Total cholesterol, triglycerides, high-density lipoprotein, apolipoprotein A1, apolipoprotein B, albumin, prealbumin, fibrinogen, troponin-T, and high-sensitivity C-reactive protein levels were not changed. Three patients complained of headache and 1 patient experienced facial flushing; however, no serious adverse effects were observed. These results suggest that beraprost sodium is effective in partially reversing the thrombogenic coagulation profile and endothelial injury in chronic peritoneal dialysis patients.
Collapse
Affiliation(s)
- Kyung Min Kim
- Division of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Hyun Woo Kim
- Division of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Jang Han Lee
- Division of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Jai Won Chang
- Division of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Jung Sik Park
- Division of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Soon Bae Kim
- Division of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| |
Collapse
|
9
|
Jiménez-González L, García-Muñoz S, Alvarez-Corral M, Muñoz-Dorado M, Rodríguez-García I. Diastereoselective Synthesis of 2-Aryl-3-vinyl-2,3-dihydrobenzo[b]furans through a Sakurai Reaction: A Mechanistic Proposal. Chemistry 2007; 13:557-68. [PMID: 17009369 DOI: 10.1002/chem.200601017] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
The condensation of 2,3-dihydrobenzoxasilepins with aromatic aldehydes in the presence of boron trifluoride to form 2,3-dihydrobenzofurans shows a level of diastereoselection which is a function of the electronic nature of the aldehyde and the polarity of the solvent. The study of the mechanism of the reaction demonstrated that it proceeds through a ring-opened allylfluorosilane, which is stable enough to be isolated and characterized.
Collapse
|
10
|
Chai SB, Hui YM, Li XM, Tang CS. Plasma Level of Mitochondrial Coupling Factor 6 Increases in Patients With Coronary Heart Disease. Circ J 2007; 71:693-7. [PMID: 17456993 DOI: 10.1253/circj.71.693] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND The aim of the present study was to investigate alterations in the plasma level of coupling factor 6 (CF6), a novel endogenous inhibitor of prostacyclin, in patients with coronary heart disease. METHODS AND RESULTS In total, 35 patients with coronary heart disease and 20 age-matched healthy subjects were examined. Plasma levels of CF6 and 6-keto-prostaglandin (PG)F(1a) (a stable metabolite of prostacyclin) were measured using radioimmunoassay. The plasma level of CF6 was significantly increased in patients (254.1+/-29.8 pg/ml vs 219.4 +/-36.7 pg/ml in controls, p<0.0001), whereas that of 6-keto-PGF(1a) was significantly decreased (23.4 +/-2.3 pg/ml vs 26.1+/-4.5 pg/ml in controls, p=0.001). Moreover, after percutaneous transluminal coronary angioplasty (PTCA) and stent therapy, the level of CF6 was further increased by 30% to 330.4+/-26.0 pg/ml, and that of 6-keto-PGF (1a) was decreased by 42% to 13.5+/-2.0 pg/ml, compared with baseline (all p<0.01). Univariate analysis showed a significant result that the plasma level of CF6 was inversely correlated with that of 6-keto-PGF(1a) in the patients. The plasma ratio of CF6 to 6-keto-PGF(1a) was 8.4 in the control group and that in patients with coronary heart disease was increased to 24.4 after the therapy from 10.9 before therapy. CONCLUSIONS The results suggest that an increased CF6 level may be responsible in part for the decreased prostacyclin level observed in patients with coronary heart disease, in particular after PTCA and stent therapy. As a potential risk factor for coronary heart disease, CF6 might have important clinical significance.
Collapse
Affiliation(s)
- San Bao Chai
- Department of Cardiovascular Disease, Beijing Fengtai Hospital, Beijing, PR China.
| | | | | | | |
Collapse
|